Gender differences in ventricular arrhythmia recurrence in patients with coronary artery disease and implantable cardioverter-defibrillators  by Lampert, Rachel et al.
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OBJECTIVES We sought to determine whether men and women with coronary artery disease (CAD) and
implantable cardioverter-defibrillators (ICDs) differ in frequency of arrhythmia recurrence
and whether gender differences are independent of clinical, electrocardiographic, and
electrophysiologic characteristics.
BACKGROUND Epidemiologic studies show that women have a lower rate of sudden cardiac death (SCD)
than men, even among patients with CAD. Whether this is due to differing susceptibilities
to ischemia or to arrhythmia is unknown.
METHODS The clinical records and ICD data disks of 340 men and 59 women with CAD who received
an ICD between June 1990 and June 2000 were reviewed. Ventricular tachycardia (VT) or
ventricular fibrillation (VF) recurrences were compared between genders and relationship
with other factors was analyzed.
RESULTS Sustained VT/VF occurred in 52% of men and 34% of women (p  0.01). Men experienced
more total VT/VF events (p  0.01), more shock-treated VT/VF events (p  0.03), more
electrical storms (p 0.001), and had VT/VF on more days in follow-up (p 0.01). Gender
differences were independent of measured clinical, electrocardiographic, and electrophysi-
ologic factors. In stratified analyses, the gender differences in VT/VF recurrence were greatest
in patients presenting with sustained monomorphic VT and those with inducible VT at
electrophysiology study.
CONCLUSIONS Women were less likely to experience VT/VF, and had fewer VT/VF episodes, than men.
These findings were strongest in patients with evidence of a stable anatomic VT circuit: those
with clinical or electrophysiologically induced VT. This study suggests that differing
susceptibility to arrhythmia triggering may underlie the known differences in SCD rates
between men and women. (J Am Coll Cardiol 2004;43:2293–9) © 2004 by the American
College of Cardiology Foundationv
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tumerous studies (1–3) of people with cardiac arrest have
hown women to have a lower rate of sudden cardiac death
SCD) than men. The prevalence of coronary artery disease
CAD), the primary cause of SCD, is lower in women (4).
owever, even among individuals with known CAD,
omen are less likely to experience SCD than are men (1,2).
hether this difference is due to lower susceptibility in
omen to recurrent ischemia or to arrhythmia is unknown.
here are few data comparing the incidence of sustained
rrhythmia between men and women, and existing studies
ave been limited to survivors of cardiac arrest (5–8).
ender differences have been noted in inducibility of
entricular arrhythmias among patients with CAD (9,10)
nd in frequency of nonsustained ventricular tachycardia
VT) in patients with congestive heart failure (11), suggest-
ng that men may have greater propensity to ventricular
rrhythmia.
Patients with implantable cardioverter-defibrillators
ICDs) provide a unique opportunity to evaluate whether
From the *Yale University School of Medicine, Department of Internal Medicine,
ew Haven, Connecticut; and †McConnell Heart Health Center, Riverside Meth-
dist Hospital, Columbus, Ohio.
Manuscript received January 14, 2004; revised manuscript received February 27,r004, accepted March 2, 2004.entricular arrhythmia recurrence differs between men and
omen. In this retrospective study of patients with CAD
nd ICDs, we investigated whether the incidence and
requency of ventricular arrhythmia recurrence differed be-
ween men and women, and whether any such differences
ere due to differences in measurable clinical, electrocardio-
raphic, or electrophysiologic factors.
ETHODS
atient population and ICD devices. The records of 650
onsecutive patients receiving an ICD with stored diagnos-
ic information at Yale University-Yale New Haven Hos-
ital between June 1990 and June 2000 were reviewed.
ollow-up was complete through September 2000. Data on
urvival and arrhythmia recurrence were censored at the
ime of last follow-up. We excluded 52 patients not yet seen
or routine first follow-up at two months, as presence of
symptomatic (pacer-terminated) VT could not be deter-
ined. We included only patients with Guidant (St. Paul,
innesota) devices, model 1705 or beyond, because during
he study years, these devices were the only ones that: 1)
tored multiple episodes (128 vs. 10 for other manufac-
urers/models); 2) stored data on disks, allowing later
etrieval of episodes; and 3) did not erase episodes on
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Gender and Arrhythmia in ICD Patients June 16, 2004:2293–9nterrogation. As the large majority of devices at our
nstitution during these years were Guidant, this resulted in
he exclusion of 64 patients (10%). Exclusion rates of men
nd women were similar for each exclusion criterion. Of the
emaining 534 patients, 399 had CAD, based on history of
ocumented myocardial infarction and/or results of coro-
ary angiography, and these constitute the study population.
ata collection. Clinical data were retrieved through a
eview of patient records. Data on ventricular arrhythmia
ecurrence were obtained by review of event details and
lectrograms stored on an ICD disk. Only episodes of VT
r ventricular fibrillation (VF) requiring ICD therapy
antitachycardia pacing or shock) for termination were
ncluded in the analysis and each episode was counted
nce, regardless of the number of therapies received.
pisodes without stored data available were not included
n the analysis.
nd points. “Ventricular tachycardia/ventricular fibrilla-
ion events” were classified based on device definitions: a
ew arrhythmia is one occurring 30 s after a shock-
erminated event or 10 s after a pacer-terminated event.
Shock-treated events” were defined as VT or VF requiring
1 shock for termination. “Electrical storm” was defined as
he occurrence of 3 separate episodes of VT/VF within a
4-h period, each separated by 5 min, regardless of mode
f termination (as defined in the Anti-arrhythmics Versus
mplantable Defibrillators [AVID] trial) (12). Because re-
etitive VT/VF occurring on a single day could potentially
kew the results, “VT/VF days,” defined as the number of
alendar days on which any VT/VF occurred, were also
nalyzed.
linical and electrocardiographic variables. Clinical and
lectrocardiographic variables measured are listed in Table
. Indications for ICD were categorized as either clinical
ustained monomorphic VT; VF (including polymorphic VT);
yncope with inducible VT at electrophysiology study (EPS);
r “MUSTT/MADIT,” defined as CAD, left ventricular
jection fraction (EF)40%, nonsustained VT, and inducible
T at EPS, as described in the Multicenter Unsustained
achycardia Trial (MUSTT) (13) and the Multicenter Auto-
Abbreviations and Acronyms
AVID  Anti-arrhythmics Versus Implantable
Defibrillators trial
CAD  coronary artery disease
ECG  electrocardiogram
EF  ejection fraction
EPS  electrophysiologic study
ICD  implantable cardioverter-defibrillator
MADIT  Multicenter Automatic Defibrillator
Implantation Trial
MUSTT  Multicenter UnSustained Tachycardia Trial
SCD  sudden cardiac death
VF  ventricular fibrillation
VT  ventricular tachycardiaatic Defibrillator Implantation Trial (MADIT) (14). Prior gevascularization was categorized as “immediate” if 1 month
receding ICD implantation, or “remote.” Wall motion was
etermined (within one year of ICD implantation) echocar-
iographically in 224 patients and by left ventriculogram in 87
atients. Coronary angiography was performed in 218 patients
nd perfusion imaging in 193 patients. Left ventricular hyper-
rophy was determined by standard electrocardiogram (ECG)
riteria and by Cornell voltage (68% test accuracy compared
ith autopsy) (15).
PS. An EPS was performed before ICD implant, in the
bsence of antiarrhythmic medication, in 334 patients. Up to
hree extrastimuli were delivered at twice the diastolic thresh-
ld at two paced cycle lengths at two right ventricular sites
apex and outflow tract). Each extrastimulus was delivered late
n systole and decremented until refractoriness or 180 ms.
ith the addition of subsequent extrastimuli, the preceding
timulus was set at the refractory period plus 20 ms. The
rotocol used was similar to that in MADIT (14,16). Studies
ere terminated with induction of sustained VT or VF or
ompletion of the protocol.
tatistical analysis. Binary variables were compared be-
ween men and women by chi-square analysis. The fre-
uency of VT/VF end points was compared using the
ilcoxon signed-rank test, as the distributions were highly
kewed (Shapiro-Wilk W test p  0.0000 for each) and
sing chi-square for linear trend (ordinal stages: 0, 1, 2 to
0, 11 to 100, 100 episodes). To determine the indepen-
ence of associations of clinical factors with VT/VF occur-
ence and frequency, logistic and linear regression analyses,
espectively, were performed. Associations are described by
dds ratios and regression coefficients (17), respectively.
linical factors having univariate associations with VT/VF
ccurrence and frequency were included as covariates for
ultivariable analysis. Separate models with ejection frac-
ion as a binary and continuous variable were evaluated. A
wo-tailed p value of 0.05 was considered significant.
tatistical analysis was performed using JMP 5.0 software
SAS Institute, Inc., Cary, North Carolina).
ESULTS
atient population. Clinical, electrocardiographic, and
lectrophysiologic data of the 340 men and 59 women are
hown in Table 1. Women were older and had more
iabetes and hypertension. Indications for ICD and revas-
ularization rates were similar between genders. Few
omen were receiving hormone replacement therapy. Men
nd women underwent evaluation of wall motion, coronary
natomy, and perfusion at similar rates. Although global
entricular function was worse in men, aneurysms were
ore prevalent in women. Number and extent of prior
nfarcts, based on number of involved territories on perfu-
ion and wall motion imaging, were similar between men
nd women, as was burden of CAD seen on catheterization.
lthough coronary anatomy, wall motion, and ECG sug-ested more anterior disease in women, this difference was
n
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June 16, 2004:2293–9 Gender and Arrhythmia in ICD Patientsot significant. On ECG, there were no differences between
en and women in presence of prolonged QRS duration,
rolonged QT interval, Q waves, or left ventricular
ypertrophy.
Men and women underwent baseline EPS at similar
ates, 83% and 86%. Sustained VT or VF was induced at
PS in 70% of men and 63% of women (p 0.31). Among
hose with ventricular arrhythmia induced, type of arrhyth-
ia, VT cycle length, mode of induction (number and
oupling interval of extrastimuli), and response to overdrive
acing did not differ between the genders.
T/VF events. During average follow-up of 30  22
onths, sustained VT/VF requiring ICD therapy occurred
n 52% of men and 34% of women (p 0.01) (Fig. 1). Men
xperienced more total VT/VF events (p  0.01) (Fig. 2).
entricular tachycardia/ventricular fibrillation occurred on
ore days in men (p  0.01), and men had more shock-
reated events (p  0.02) and more electrical storms (p 
.001) (Table 2). After normalization of event frequencies
o months of follow-up, all end points remained signifi-
antly more frequent in men (p  0.01 for each.)
In 17 patients, all men, the number of treated episodes
efined as VT or VF by the device exceeded the storage
able 1. Continued
Men Women p
erfusion imaging N  168 N  25
Ischemia present 72 (43%) 8 (32%) 0.30
Scar present 128 (76%) 19 (76%) 0.98
Any anterior abnormality 65 (42%) 12 (55%) 0.22
Anterior plus other abnormality 42 (27%) 8 (37%) 0.37
lectrocardiographic characteristics N  298 N  54
QRS  120 ms 85 (28%) 12 (22%) 0.3
Left bundle branch block 57 (19%) 8 (15%) 0.7
QT  440 ms‡ 31 (15%) 2 (5%) 0.06
QTc  440 ms‡ 55 (25%) 10 (26%) 0.9
Q-waves—any§ 139 (58%) 26 (57%) 0.88
Q-waves—anterior§ 64 (27%) 13 (37%) 0.15
Left ventricular hypertrophy‡ 28 (13%) 5 (12%) 0.81
Cornell voltage (mV)‡ 1.8  0.1 1.5  0.1 0.08
Cornell voltage 2.0‡ 64 (30%) 12 (28%) 0.82
lectrophysiologic parameters N  283 N  51
Refractory period (at CL
400 ms) (ms)
233  1.3 233  3.1 0.92
Any VT/VF induced 198 (70%) 32 (63%) 0.31
Arrhythmia induced 0.8
Monomorphic VT—
pacer-terminated
146 (74%) 24 (75%)
Monomorphic VT—
cardioverted
42 (21%) 7 (22%)
VF 10 (5%) 1 (3%)
Induced with 1–2 extra-stimuli 95 (48%) 20 (62%) 0.13
Coupling interval final
extra-stimulus
237  2.7 248  6.6 0.14
CL (VT only, ms) 275  4.3 284  10.7 0.46
ata presented as number (%) or mean  standard error. *Defined in text. †Patients
ith regional abnormalities. ‡Excluding patients with QRS120 ms. §Excluding
atients with left bundle branch block.
CABG coronary artery bypass graft; CL cycle length; EF ejection fraction;
CD  implantable cardioverter-defibrillator; LAD  left anterior descending
oronary artery; VF  ventricular fibrillation; VT  ventricular tachycardia.able 1. Clinical, Electrocardiographic, and Electrophysiologic
haracteristics
Men Women p
340 59
onths follow-up 30  1 26  3 0.1
ge 67  0.5 70  1.3 0.045
CD indication 0.99
VF 79 (23%) 15 (26%)
Sustained VT 129 (38%) 21 (36%)
Syncope 59 (17%) 9 (16%)
MUSTT/MADIT* 66 (19%) 11 (19%)
iabetes 65 (19%) 18 (30%) 0.053
ypertension 125 (37%) 31 (52%) 0.027
evascularization—remote* 0.17
CABG 134 (40%) 17 (28%)
Percutaneous coronary
intervention
23 (7%) 7 (12%)
None 178 (53%) 35 (59%)
evascularization—immediate* 0.28
CABG 44 (13%) 11 (18%)
Percutaneous coronary
intervention
36 (11%) 9 (15%)
None 255 (76%) 39 (66%)
ny preceding CABG 178 (53%) 27 (45%) 0.23
evascularization/transplant—
in follow-up
20 (6%) 9 (15%) 0.02
edications
ospital discharge (after ICD
implantation)
Beta-blockers 141 (44%) 21 (37%) 0.35
Any antiarrhythmic agent 99 (30%) 18 (32%) 0.7
Amiodarone 32 (10%) 6 (11%) 0.84
Sotalol 18 (6%) 8 (14%) 0.03
Class I antiarrhythmic agents 60 (19%) 7 (12%) 0.47
Hormone replacement therapy — 4 (8%)
ollow-up
Beta-blockers 177 (55%) 23 (41%) 0.05
Any antiarrhythmic agent 143 (43%) 20 (36%) 0.32
Amiodarone 75 (23%) 10 (18%) 0.34
Sotalol 35 (11%) 7 (13%) 0.74
Class I antiarrhythmic agents 95 (30%) 11 (20%) 0.12
Hormone replacement therapy — 5 (10%)
entricular function N  262 N  49
EF (%) 31  0.7 35  1.7 0.014
EF 40% 261 (83%) 38 (70%) 0.042
Overall wall motion
Regional abnormality 196 (75%) 39 (80%) 0.12
Diffusely abnormal 41 (16%) 3 (6%)
Normal 25 (10%) 7 (14%)
Severity†
Aneurysm 37 (16%) 16 (38%) 0.01
Akinesis 92 (38%) 16 (38%)
Hypokinesis 108 (46%) 10 (24%)
Anterior abnormality present† 89 (40%) 21 (51%) 0.15
Anterior plus other abnormality† 57 (25%) 8 (18%) 0.4
oronary anatomy N  185 N  33
Number of diseased vessels
(70% stenosis)
0 28 (15%) 1 (3%) 0.2
1 73 (40%) 17 (52%)
2 45 (24%) 7 (21%)
3 39 (21%) 8 (24%)
LAD disease 94 (61%) 25 (78%) 0.06
Continued
apacity of the ICD. Numbers of total confirmed VT/VF
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Gender and Arrhythmia in ICD Patients June 16, 2004:2293–9vents in these patients ranged from 90 to 1,105; numbers of
nconfirmed events (not included in the analyses) ranged
rom 297 to 5,973.
Survival after ICD implantation did not differ between
en and women (Fig. 3).
linical, electrocardiographic, and electrophysiologic
actors. In univariate analysis (Table 3), male gender,
resentation with sustained VT, EF 40%, presence of
neurysm, absence of remote and immediate revascular-
zation, use of antiarrhythmic medications at discharge,
bsence of beta-blockers at discharge, prolonged QRS,
rolonged QT, and induction of ventricular arrhythmia
t EPS were associated with greater occurrence of both
ny VT/VF event and frequency of VT/VF events.
iabetes was associated with a lower likelihood of
ecurrent arrhythmia. Other measured variables (Table 1)
id not show significant univariate associations with end
oints. In a multivariable analysis including these factors,
en remained more than twice as likely as women to
ndergo any VT/VF event (adjusted odds ratio 2.20, 95%
onfidence interval 1.02 to 4.90, p  0.05) and had
reater frequency of events (p  0.05). In addition to
ender, factors independently associated with both end
oints in multivariable analysis included presentation
ith sustained VT, inducible VT at EPS, and absence of
mmediate and remote revascularization.
To evaluate whether the gender difference in VT/VF was
redominant in any clinical subgroups, stratified analysis
as performed, initially based on indication for ICD. Men
ad greater occurrence and frequency of VT/VF end points
mong patients with a history of sustained VT and among
hose with “MUSTT/MADIT” criteria (13,14), but not
mong patients presenting with VF (Fig. 1). Also, after
tratification by presence of induced arrhythmia, male gen-
igure 1. Incidence of any ventricular tachycardia (VT)/ventricular fibril-
ation (VF) after implantable cardioverter-defibrillator (ICD) implantation
n men versus women, for the entire population and by indication for
mplantable cardioverter-defibrillator. MADIT  Multicenter Automatic
efibrillator Implantation Trial; MUSTT  Multicenter UnSustained
achycardia Trial.er predicted VT/VF occurrence and frequency for all end goints in those patients with inducible arrhythmia, but not
hose without (all p  0.05).
ISCUSSION
n this study of patients with CAD and ventricular arrhyth-
ias treated with ICDs, gender was an important determi-
ant of arrhythmia recurrence. Men were more likely to
xperience ventricular arrhythmias in follow-up and had
ore frequent total VT/VF events and more follow-up days
n which VT/VF occurred. More severe arrhythmias
shock-treated events and electrical storms) were also more
requent in men. Male gender remained a significant pre-
ictor of VT/VF after adjustment for measured clinical,
lectrocardiographic, and electrophysiologic factors associ-
ted with arrhythmia recurrence. These findings were stron-
est in those patients with evidence of a stable anatomic VT
ircuit: those with clinical or induced sustained monomor-
hic VT.
In the Framingham study, the age-adjusted SCD risk for
omen was one-half that in men, and among patients with
AD one-fourth that in men, a difference not explained by
isk-factor burden (1). The gender difference in SCD
ncidence could reflect greater male susceptibility to isch-
mia and/or arrhythmia. Although ischemic disease is
nown to occur less frequently in women (4), rates of
rrhythmia recurrence have been less well described. The
urrent findings suggest that the lower SCD rate in women
ith CAD may be due at least in part to a gender difference
n propensity to triggering of arrhythmia.
omparison with previous studies. Several previous stud-
es have shown no difference in arrhythmia occurrence after
CD implantation between genders (5,7,18); one showed an
ncreased incidence of shock in women (6). However, all
tudies analyzed populations of arrest or VF survivors with
iverse underlying heart diseases. Similarly, in the current
tudy, among patients presenting with VF there was no
igure 2. Distribution of ventricular arrhythmia frequency by gender.
odified box-plot: thick lines  median, center lines  75th percentile,
nd top lines  90th percentile; whiskers  maximum event frequencies.
vent frequency is expressed in percentiles because of skewness of
istribution.ender difference in arrhythmia recurrence.
P
s
p
s
d
t
r
i
t
d
h
t
w
s
a
m
f
a
i
g
w
u
p
t
s
d
o
w
g
t
p
t
c
i
t
(
F
g
e
d
a
s
l
d
Q
V
p
p
m
n
a
g
w
m
w
V
s
e
e
a
m
m
d
n
T
*
c
F
i
w
2297JACC Vol. 43, No. 12, 2004 Lampert et al.
June 16, 2004:2293–9 Gender and Arrhythmia in ICD Patientsotential mechanisms. The gender differences seen in this
tudy cannot be explained by clinical factors shown to
redict arrhythmia recurrence in patients with CAD. Con-
istent with previous studies (8,19), we found few clinical
ifferences between men and women with CAD and ven-
ricular arrhythmias. Multiple factors associated with ar-
hythmia occurrence or mortality in arrhythmia patients,
ncluding indication for ICD (5,7), preceding revasculariza-
ion (20,21), extent (22) and site (23) of infarcted myocar-
ium, prolonged QRS duration (24), and left ventricular
ypertrophy (2,25), did not differ between genders. Al-
hough two factors potentially protective from arrhythmia
ere greater in women, specifically EF (a predictor of ICD
hock [7]) and diabetes (associated with lower rates of
rrhythmia in this and previous studies [26]), gender re-
ained an independent predictor after adjustment for these
actors. Aneurysm, linked with sustained VT (27) and
rrhythmic (28) and total (29) mortality, was more prevalent
n women, underscoring the fact that although arrhythmo-
enic substrate was similar or greater, women’s arrhythmias
ere triggered less often. The physiologic mechanisms that
nderlie this phenomenon remain unknown. Possible ex-
lanations include differences in electrophysiologic proper-
ies and/or in autonomic response to triggering factors.
able 2. Ventricular Arrhythmia Frequency
Number of
Events
Total VT/VF Events* VT/VF D
Men Women Men
0 161 (47%) 39 (66%) 161 (47%)
1 20 (6%) 5 (8%) 29 (8%)
2–10 72 (21%) 10 (17%) 89 (26%)
11–100 52 (15%) 3 (5%) 51 (15%)
100 35 (10%) 2 (3%) 11 (3%)
p  0.01, †p  0.02, ‡p  0.001 (chi square for linear trend). Data are presented as
olumn.
Abbreviations as in Table 1.
igure 3. Kaplan-Meier survival curve comparing total mortality after
mplantable cardioverter-defibrillator implantation between men andvomen.Cellular, animal, and human investigations have demon-
trated electrophysiologic differences between genders, some
ependent on circulating sex hormones, others independent
f ambient hormonal milieu. Prolonged repolarization in
omen has been well described (30). Experimentally, estro-
en affects potassium-channel protein synthesis, which al-
ers repolarization (31) and can increase atrial refractory
eriods (32). However, studies of hormone replacement
herapy in postmenopausal women (33) and of cyclical
hanges in premenopausal women (34) have not shown an
nfluence of circulating estrogens on repolarization. Testos-
erone alters potassium currents in patch-clamp experiments
35) and alters the QT interval in castrated men (36).
urther, electrophysiologic substrate may differ between
enders even in the absence of circulating hormones. For
xample, myocytes isolated from female rabbits show re-
uced outward potassium current density (37) and longer
ction potential duration (38). However, in the current
tudy no differences were seen in ECG measures of repo-
arization (QT/QTc). It is likely that the extent of myocar-
ial disease became a more important determinant of
T/QTc than gender.
Previous data are conflicting with regard to inducibility of
T during EPS in women with CAD (8–10,39). In this
opulation, with history of clinical or induced arrhythmia,
revalence of inducible VT was not significantly greater in
en. Although inducible arrhythmia was a strong determi-
ant of future VT/VF events in this study and others (7,40),
djustment for inducibility did not alter the associations of
ender and arrhythmia. Surprisingly, it was those patients
ith the most homogeneous profile, clinical sustained
onomorphic VT and/or inducibility of VT at EPS, in
hom gender most strikingly predicted spontaneous
T/VF recurrence. This suggests that it is differences in
usceptibility to arrhythmia triggering, not in the underlying
lectrophysiologic substrate, that mediate the gender differ-
nces in arrhythmia recurrence.
Previous studies have demonstrated gender differences in
utonomic nervous system function. Resting vagal tone, as
easured by heart rate variability, is higher in women in
ost (41,42), although not all (43), studies. This may be
ue to circulating hormones (41), as estrogen alters norepi-
ephrine release (44). However, the gender difference in
Shock-Treated Events† Electrical Storms‡
men Men Women Men Women
66%) 189 (56%) 44 (75%) 234 (69%) 55 (93%)
10%) 24 (7%) 6 (10%) 28 (8%) 0
19%) 75 (22%) 7 (12%) 43 (13%) 3 (5%)
5%) 46 (14%) 2 (4%) 32 (9%) 1 (2%)
0 1 (0.3%) 0 3 (1%) 0
er (percent) of individuals with arrhythmia frequency in each range listed in leftmostays*
Wo
39 (
6 (
11 (
3 (
numbagal tone persists in elderly women (42), suggesting that
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Gender and Arrhythmia in ICD Patients June 16, 2004:2293–9he autonomic differences between men and women may be
ntrinsic. Also, women have less sympathetic response to
nduced mental stress (45). As sympathetic activation can
nfluence arrhythmia occurrence and severity (46,47), dif-
erences in autonomic response may underlie the gender
ifferences in arrhythmia seen in the current study.
Although women had fewer arrhythmia recurrences than
en, a substantial number did have potentially life-
hreatening ventricular arrhythmias treated by the ICD, and
urvival after ICD implantation did not differ between
enders. Clearly, both genders benefit from ICD therapy, as
ound in the AVID trial (48).
tudy limitations. The ICDs in this study had the largest
torage capabilities available, but in some patients tachyar-
hythmia episodes exceeded device memory, resulting in the
otential loss of data. As these episodes occurred only in
en, the current findings are likely an underestimation of
he magnitude of the gender difference. Also, in this
etrospective study, not all patients had undergone all
iagnostic assessments. However, men and women under-
ent EPS and imaging studies in similar proportions,
aking systematic bias unlikely. Functional capacity was
ot tested in most patients, and New York Heart Associa-
ion functional class, correlated in univariate analysis with
ppropriate ICD shock in previous studies (although mul-
ivariate analysis was not performed in these studies
49,50]), was not recorded consistently. However, because
tructural heart disease as measured by multiple imaging
tudies was similar in men and women, it is unlikely that
otential unmeasured differences in New York Heart Asso-
iation functional class are the primary source of the gender
ifference in arrhythmia. Future investigation of congestive
eart failure as a potential trigger for arrhythmia in men and
omen is warranted. Also, postmortem ICD interrogation
as not performed. Whether gender differences exist in
rrhythmia recurrence near the patient’s end of life requires
urther investigation. As in previous studies (8,13,14,39,48),
Table 3. Univariate Associations With VT/VF
A
Odd
(95
Male gender 2.13 (1
Clinical sustained VT 3.03 (1
EF  40% 1.79 (1
Diabetes 0.6 (0
Absence of remote revascularization 1.67 (1
Absence of immediate revascularization 1.87 (1
Beta-blockers (at discharge) 0.62 (0
Anti-arrhythmic agents (at discharge) 1.8 (1
Presence aneurysm 1.86 (1
QRS  120 ms 2.7 (1
QT  440 ms 2.19 (1
Ventricular arrhythmia induced 2.83 (1
*Logistic regression. †Linear regression.
CI  confidence interval. Other abbreviations as in Tablhere were relatively small numbers of women in ouropulation, but the gender difference remained significant
n evaluation of multiple end points and controlling for
ultiple potential confounders.
onclusions. This study demonstrates a significant differ-
nce in arrhythmia occurrence and frequency between men
nd women with CAD and ICDs. Women were less likely
han men to experience ventricular arrhythmias in follow-up
nd had fewer arrhythmias when they did recur. These
ender differences were not explained by measured clinical,
lectrocardiographic, or electrophysiologic factors. Deter-
ining the mechanisms underlying these differences re-
uires further investigation. This study suggests that differ-
ng susceptibility to arrhythmia triggering may underlie the
nown differences in SCD rates between men and women.
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